Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
CANTON, Mass., April 08, 2016 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that Michael Heffernan, the Company’s CEO, will present at the 15th Annual Needham Healthcare Conference in New York City. The presentation will take place at 1:40 p.m. ET on Wednesday, April 13, 2016 at the Westin Grand Central Hotel.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza™ ER
Collegium's lead product candidate, Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone, in development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Collegium developed Xtampza using its proprietary DETERx technology platform to address common methods of abuse, including chewing, crushing and/or dissolving, and then taking it orally or snorting or injecting.
Contact: Douglas Carlson Vice President, Corporate Development [email protected]
